OCUGEN, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.40 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.44, a 61.80% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.89, a 27.14% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.70, a 42.62% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.22, a 72.40% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.96, a 0.00% change from fiscal 2024.
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.96, a 6.80% decline from fiscal 2023.
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.03.
- OCUGEN, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $1.21, a 30.46% decline from fiscal 2017.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.40 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $1.44 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $0.96 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $0.93 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $0.90 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $0.89 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $0.96 10-K · filed 2025-03-05 | |||
| 2024-09-30 | $0.96 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $0.93 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.70 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $1.03 10-K · filed 2024-04-16 | |||
| 2023-09-30 | $1.06 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.07 10-Q · filed 2023-08-21 | |||
| 2023-03-31 | $1.22 10-Q · filed 2023-05-05 | |||
| 2022-09-30 | $3.90 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $3.99 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $4.42 10-Q · filed 2022-05-06 | |||
| 2021-09-30 | $3.33 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $3.13 10-Q · filed 2021-08-06 | |||
| 2018-12-31 | $1.21 10-K · filed 2019-03-22 | |||
| 2018-09-30 | $2.38 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $2.68 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $2.63 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $1.74 10-K · filed 2018-03-15 | |||
| 2017-09-30 | $1.72 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $1.71 10-Q · filed 2017-08-10 | |||
| 2017-03-31 | $1.72 10-Q · filed 2017-05-11 | |||
| 2016-12-31 | $2.02 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $2.51 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | $2.50 10-Q · filed 2016-08-11 | |||
| 2016-03-31 | $2.56 10-Q · filed 2016-05-12 | |||
| 2015-12-31 | $7.74 10-K · filed 2016-03-10 | |||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-12 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |